Slight downturn in Boston Scientifics Q2

Interventional device developer Boston Scientific revenues and adjusted net income showed a slight dip for its fiscal 2007 second quarter, end-June 30, compared with results from the Natick, Mass.-based firm’s 2006 second quarter results.

For the period, net sales were $2.071 billion, compared with $2.110 billion for the second quarter of 2006 and $2.086 billion for the first quarter of 2007. Adjusted net income for the quarter, excluding net special charges and amortization and stock compensation expense, was $271 million. Adjusted net income for the second quarter of 2006, excluding net special charges and amortization and stock compensation expense, was $412 million.

The company said that it estimates net sales for the third quarter this year to be between $2 billion and $2.1 billion.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup